Diana Brainard
Net worth: 132 918 $ as of 2026-06-29
Net worth: 132 918 $ as of 2026-06-29
Diana M.
Brainard is currently an Independent Director at Nektar Therapeutics since 2021 and an Independent Director at Affinia Therapeutics, Inc. since 2022.
Formerly, served as Chief Executive Officer & Director at AlloVir, Inc. from 2021 to 2024, Senior VP-HIV & Emerging Viral Infections at Gilead Sciences, Inc. from 2018 to 2021, and Partner at MPM BioImpact LLC.
Education includes an undergraduate degree from Brown University in 1992 and a doctorate from Tulane University School of Medicine in 1997.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NEKTAR THERAPEUTICS 0.01% | 2026-04-05 | 1,904 ( 0.01% ) | 132 918 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| NEKTAR THERAPEUTICS | Director/Board Member | 2021-11-10 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Director/Board Member | 2022-03-07 |
| Companies | Position | End |
|---|---|---|
| ALLOVIRPAR | Chief Executive Officer | 2024-12-18 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2020-12-31 |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Nektar Therapeutics
Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Tulane University School of Medicine
Tulane University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AlloVir, Inc.
AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions